These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38101756)

  • 1. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
    J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
    Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Pronk MAMCB; Beuers UHW; van der Meer AJ; van Gerven NMF; Sijtsma MGM; Verwer BJ; Gisbertz IAM; Bartelink M; van den Brand FF; Sebib Korkmaz K; van den Berg AP; Guichelaar MMJ; Soufidi K; Levens AD; van Hoek B; Drenth JPH;
    Trials; 2022 Dec; 23(1):1012. PubMed ID: 36514163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of mycophenolate mofetil
    Dalekos GN; Arvaniti P; Gatselis NK; Gabeta S; Samakidou A; Giannoulis G; Rigopoulou E; Koukoulis GK; Zachou K
    JHEP Rep; 2022 Dec; 4(12):100601. PubMed ID: 36411768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial.
    Stoelinga AEC; Tushuizen ME; van den Hout WB; Girondo MDMR; de Vries ES; Levens AD; Moes DAR; Gevers TJG; van der Meer S; Brouwer HT; de Jonge HJM; de Boer YS; Beuers UHW; van der Meer AJ; van den Berg AP; Guichelaar MMJ; Drenth JPH; van Hoek B;
    Trials; 2024 Jan; 25(1):61. PubMed ID: 38233878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.
    Dalekos GN; Arvaniti P; Gatselis NK; Samakidou A; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K
    Front Immunol; 2021; 12():798602. PubMed ID: 35087524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
    Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
    J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis.
    Zachou K; Gatselis NK; Arvaniti P; Gabeta S; Rigopoulou EI; Koukoulis GK; Dalekos GN
    Aliment Pharmacol Ther; 2016 May; 43(10):1035-47. PubMed ID: 26991238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
    Orth T; Peters M; Schlaak JF; Krummenauer F; Wanitschke R; Mayet WJ; Galle PR; Neurath MF
    Am J Gastroenterol; 2000 May; 95(5):1201-7. PubMed ID: 10811328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
    Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
    Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
    Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
    Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
    Liberal R; Gaspar R; Lopes S; Macedo G
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
    Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine.
    Giannakopoulos G; Verbaan H; Friis-Liby IL; Sangfelt P; Nyhlin N; Almer S;
    Dig Liver Dis; 2019 Feb; 51(2):253-257. PubMed ID: 30389427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
    Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
    Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
    Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
    Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
    Wolf DC; Bojito L; Facciuto M; Lebovics E
    Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.
    Hiemstra TF; Walsh M; Mahr A; Savage CO; de Groot K; Harper L; Hauser T; Neumann I; Tesar V; Wissing KM; Pagnoux C; Schmitt W; Jayne DR;
    JAMA; 2010 Dec; 304(21):2381-8. PubMed ID: 21060104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.